280 related articles for article (PubMed ID: 29600004)
1. Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis.
You S; Saxena A; Wang X; Tan W; Han Q; Cao Y; Liu CF
Stroke Vasc Neurol; 2018 Mar; 3(1):22-27. PubMed ID: 29600004
[TBL] [Abstract][Full Text] [Related]
2. Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review.
Wang X; You S; Sato S; Yang J; Carcel C; Zheng D; Yoshimura S; Anderson CS; Sandset EC; Robinson T; Chalmers J; Sharma VK
Stroke Vasc Neurol; 2018 Mar; 3(1):28-33. PubMed ID: 29600005
[TBL] [Abstract][Full Text] [Related]
3. Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis.
Dong Y; Han Y; Shen H; Wang Y; Ma F; Li H; Wang Y; Dong Q
Stroke Vasc Neurol; 2020 Dec; 5(4):348-352. PubMed ID: 32611728
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of the Telestroke Drip-And-Stay Model: A Systematic Review and Meta-Analysis.
Waseem H; Salih YA; Burney CP; Abel MA; Riblet N; Kim A; Robbins N
J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105638. PubMed ID: 33540336
[TBL] [Abstract][Full Text] [Related]
6. Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Taking Warfarin with Subtherapeutic INR.
Mowla A; Memon A; Razavi SM; Lail NS; Vaughn CB; Mohammadi P; Sawyer RN; Shirani P
J Stroke Cerebrovasc Dis; 2021 May; 30(5):105678. PubMed ID: 33640783
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue plasminogen activator: a systematic review and meta-analysis.
Guo Y; Yang Y; Zhou M; He L
Stroke Vasc Neurol; 2018 Dec; 3(4):203-208. PubMed ID: 30637125
[TBL] [Abstract][Full Text] [Related]
8. Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard?
Dong Y; Cao W; Cheng X; Fang K; Wu F; Yang L; Xie Y; Dong Q
Stroke Vasc Neurol; 2016 Sep; 1(3):115-121. PubMed ID: 28959472
[TBL] [Abstract][Full Text] [Related]
9. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
Ong CT; Wong YS; Wu CS; Su YH
Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
[TBL] [Abstract][Full Text] [Related]
10. Dual antiplatelet therapy versus intravenous tissue plasminogen activator with acute minor ischemic stroke: A systematic review and meta-analysis of safety and efficacy.
Abbas A; Hamad AA; El Din Moawad MH; Ewis DK; Youssef RA; Hamouda H; Hassan MA; Aladawi M; Elfil M; Meshref M; Al-Mufti F
J Stroke Cerebrovasc Dis; 2024 Jul; 33(7):107704. PubMed ID: 38561167
[TBL] [Abstract][Full Text] [Related]
11. Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke.
Shah S; Liang L; Kosinski A; Hernandez AF; Schwamm LH; Smith EE; Fonarow GC; Bhatt DL; Feng W; Peterson ED; Xian Y
Circ Cardiovasc Qual Outcomes; 2020 Jan; 13(1):e006031. PubMed ID: 31903770
[TBL] [Abstract][Full Text] [Related]
12. Low- versus Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: An Updated Meta-Analysis.
Liu H; Zheng H; Cao Y; Pan Y; Wang D; Zhang R; You S; Zhang X; Li S; Tong X; Liu CF; Wang Y
J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):988-997. PubMed ID: 29224744
[TBL] [Abstract][Full Text] [Related]
13. Treating ischaemic stroke with intravenous tPA beyond 4.5 hours under the guidance of a MRI DWI/T2WI mismatch was safe and effective.
Bai QK; Zhao ZG; Lu LJ; Shen J; Zhang JY; Sui HJ; Xie XH; Chen J; Yang J; Chen CR
Stroke Vasc Neurol; 2019 Mar; 4(1):8-13. PubMed ID: 31105973
[TBL] [Abstract][Full Text] [Related]
14. Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.
Whiteley WN; Thompson D; Murray G; Cohen G; Lindley RI; Wardlaw J; Sandercock P;
Stroke; 2014 Apr; 45(4):1000-6. PubMed ID: 24603072
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore.
Sharma VK; Tsivgoulis G; Tan JH; Wong LY; Ong BK; Chan BP; Teoh HL
J Stroke Cerebrovasc Dis; 2010; 19(6):424-30. PubMed ID: 20554224
[TBL] [Abstract][Full Text] [Related]
16. Intravenous tissue plasminogen activator for patients with minor ischemic stroke.
Huisa BN; Raman R; Neil W; Ernstrom K; Hemmen TM
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):732-6. PubMed ID: 21531576
[TBL] [Abstract][Full Text] [Related]
17. Intravenously administered tissue plasminogen activator useful in milder strokes? A meta-analysis.
Yeo LLL; Ho R; Paliwal P; Rathakrishnan R; Sharma VK
J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2156-2162. PubMed ID: 25113080
[TBL] [Abstract][Full Text] [Related]
18. Utility of Computed Tomographic Perfusion in Thrombolysis for Minor Stroke.
Ng FC; Coote S; Frost T; Bladin C; Choi PM
Stroke; 2016 Jul; 47(7):1914-6. PubMed ID: 27197850
[TBL] [Abstract][Full Text] [Related]
19. Generalized Safety and Efficacy of Simplified Intravenous Thrombolysis Treatment (SMART) Criteria in Acute Ischemic Stroke: The MULTI SMART Study.
Sørensen SB; Barazangi N; Chen C; Wong C; Grosvenor D; Rose J; Bedenk A; Morrow M; McDermott D; Hove JD; Tong DC
J Stroke Cerebrovasc Dis; 2016 May; 25(5):1110-1118. PubMed ID: 26897101
[TBL] [Abstract][Full Text] [Related]
20. Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18-64 years in the USA.
Joo H; Wang G; George MG
Stroke Vasc Neurol; 2016 Mar; 1(1):8-15. PubMed ID: 27547449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
